Literature DB >> 19214541

[Comment of the Society of Pediatric and Adolescent Rheumatology on the US Food and Drug Administration (FDA) announcement regarding cases of malignancy in anti-TNF-treated patients].

T Hospach1, J P Haas, H I Huppertz, R Keitzer, H Michels, R Trauzeddl, D Föll, G Dannecker, G Horneff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19214541     DOI： 10.1007/s00393-008-0426-y

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  23 in total

1.  Hodgkin's lymphoma associated with anti-TNF use in juvenile idiopathic arthritis: supplemental case report.

Authors:  Lisa Imundo
Journal:  J Rheumatol       Date:  2008-08       Impact factor: 4.666

2.  Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

Authors:  Eva Baecklund; Anastasia Iliadou; Johan Askling; Anders Ekbom; Carin Backlin; Fredrik Granath; Anca Irinel Catrina; Richard Rosenquist; Nils Feltelius; Christer Sundström; Lars Klareskog
Journal:  Arthritis Rheum       Date:  2006-03

3.  Incidence of occult cancer in children presenting with musculoskeletal symptoms: a 10-year survey in a pediatric rheumatology unit.

Authors:  S Trapani; F Grisolia; G Simonini; G B Calabri; F Falcini
Journal:  Semin Arthritis Rheum       Date:  2000-06       Impact factor: 5.532

Review 4.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors:  Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

5.  Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.

Authors:  P Geborek; A Bladström; C Turesson; A Gulfe; I F Petersson; T Saxne; H Olsson; L T H Jacobsson
Journal:  Ann Rheum Dis       Date:  2005-02-04       Impact factor: 19.103

6.  Malignancy and biologic therapy in rheumatoid arthritis.

Authors:  Johan Askling; Tim Bongartz
Journal:  Curr Opin Rheumatol       Date:  2008-05       Impact factor: 5.006

7.  Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience.

Authors:  Larry W Moreland; Michael E Weinblatt; Edward C Keystone; Joel M Kremer; Richard W Martin; Michael H Schiff; James B Whitmore; Barbara W White
Journal:  J Rheumatol       Date:  2006-03-15       Impact factor: 4.666

8.  Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.

Authors:  G Horneff; F De Bock; I Foeldvari; H J Girschick; H Michels; D Moebius; H Schmeling
Journal:  Ann Rheum Dis       Date:  2008-04-15       Impact factor: 19.103

9.  Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.

Authors:  Daniel J Lovell; Andreas Reiff; Norman T Ilowite; Carol A Wallace; Yun Chon; Shao-Lee Lin; Scott W Baumgartner; Edward H Giannini
Journal:  Arthritis Rheum       Date:  2008-05

10.  Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.

Authors:  M Schiff; M Keiserman; C Codding; S Songcharoen; A Berman; S Nayiager; C Saldate; T Li; R Aranda; J-C Becker; C Lin; P L N Cornet; M Dougados
Journal:  Ann Rheum Dis       Date:  2007-11-29       Impact factor: 19.103
View more
  2 in total

Review 1.  [Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis].

Authors:  G Horneff
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372

2.  [Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA's report regarding malignancies in anti-TNF-treated patients from Aug. 4, 2009].

Authors:  G Horneff; T Hospach; G Dannecker; D Föll; J P Haas; H J Girschick; H I Huppertz; R Keitzer; H J Laws; H Michels; K Minden; R Trauzeddel
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.